OverviewSuggest Edit

Applied Genetic Technologies is a clinical-stage biotechnology company, which develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. The Company’s lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

TypePublic
Founded1991
HQAlachua, FL, US
Websiteagtc.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Jun 2019)85(+9%)
Revenue (FY, 2020)$2.5 M(-94%)
Share Price (Dec 2021)$1.9(-4%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Applied Genetic Technologies

Stephen W. Potter

Stephen W. Potter

Chief Business Officer
david R. Knop

david R. Knop

Vice President of Process Development
Sue Washer

Sue Washer

President, CEO
Brian Krex

Brian Krex

General Counsel
Show more

Applied Genetic Technologies Office Locations

Applied Genetic Technologies has offices in Alachua and Cambridge
Alachua, FL, US (HQ)
14193 NW 119th Terrace Ste 10
Cambridge, MA, US
One Kendall Square, Binney St
Show all (2)

Applied Genetic Technologies Financials and Metrics

Applied Genetic Technologies Revenue

Applied Genetic Technologies's revenue was reported to be $2.45 m in FY, 2020
USD

Net income (Q3, 2021)

(14.9m)

EBIT (Q3, 2021)

(14.5m)

Market capitalization (31-Dec-2021)

84.9m

Closing stock price (31-Dec-2021)

1.9

Cash (31-Mar-2021)

89.5m

EV

6.3m
Applied Genetic Technologies's current market capitalization is $84.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.1m2.4m47.4m39.5m24.2m41.7m2.5m

Revenue growth, %

109%1912%

General and administrative expense

5.2m10.4m10.6m11.4m14.4m13.6m

R&D expense

8.5m16.5m38.9m26.2m32.2m33.2m35.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

232.0k705.0k652.0k284.0k11.1m12.2m12.0m11.8m10.9m8.4m10.3m4.9m3.6m14.0m5.9m21.3m

General and administrative expense

1.4m1.7m1.9m2.6m3.2m2.1m2.4m2.8m3.1m3.4m3.3m3.5m

R&D expense

2.1m4.4m3.4m4.1m17.0m7.2m7.9m5.6m6.0m6.3m8.3m7.7m7.4m10.1m7.6m7.2m8.6m8.3m11.6m11.8m11.0m

Operating expense total

3.5m6.1m5.4m6.7m20.3m9.3m10.2m8.4m6.0m6.3m8.3m7.7m7.4m10.1m7.6m7.2m8.6m11.4m15.1m15.1m14.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.6m39.2m28.9m30.7m31.1m26.7m38.5m

Accounts Receivable

14.1m56.1k

Prepaid Expenses

3.4m4.0m2.3m2.5m

Inventories

1.2m17.5m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

8.0m46.8m44.2m44.5m140.3m44.4m17.9m56.0m42.5m35.5m48.7m70.3m47.6m26.5m24.0m21.6m16.3m58.5m31.6m19.1m89.5m

Accounts Receivable

700.0k900.0k800.0k

Prepaid Expenses

690.0k1.2m1.1m1.6m1.9m1.9m2.1m2.5m2.6m3.8m3.2m4.0m4.0m2.5m3.0m2.9m2.1m2.9m2.0m2.1m2.0m

Current Assets

25.6m93.1m77.4m65.1m173.8m152.8m136.8m135.9m120.0m135.7m128.6m123.9m115.9m108.2m99.2m92.2m73.2m87.5m68.5m55.2m113.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(15.9m)(24.3m)(1.4m)407.0k(21.3m)(2.0m)(45.9m)

Depreciation and Amortization

334.0k376.0k567.0k912.0k1.2m1.4m1.3m

Inventories

(1.2m)(826.0k)

Accounts Payable

156.0k228.0k140.0k(333.0k)(53.0k)327.0k83.0k
USDQ3, 2014

Financial Leverage

-0.6 x
Show all financial metrics

Applied Genetic Technologies Operating Metrics

FY, 2015FY, 2016

Patents Licensed

6473
Show all operating metrics

Applied Genetic Technologies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Applied Genetic Technologies Online and Social Media Presence

Embed Graph

Applied Genetic Technologies News and Updates

Thinking about buying stock in Eloxx Pharmaceuticals, Sio Gene Therapies, Ampio Pharmaceuticals, Applied Genetic Technologies, or Cyclo Therapeutics?

NEW YORK, June 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELOX, SIOX, AMPE, AGTC, and CYTH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Applied Genetic Technologies Blogs

AGTC Appoints Hope D’Oyley-Gay as General Counsel

November 11, 2021 at 8:00 AM EST PDF Version Ms. D’Oyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) — Applied Genetic…

AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa

October 12, 2021 at 11:08 AM EDT PDF Version GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatme…

AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study

September 9, 2021 at 8:00 AM EDT PDF Version AGTC patient advocacy executive director and director of patient enrollment to speak at Clinical Trials in Rare Diseases Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq:…

AGTC to Host Conference Call to Discuss Achromatopsia 12-Month Data in its Ongoing Phase 1/2 Clinical Trials

June 23, 2021 at 4:03 PM EDT GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retin…

AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica

AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial May 6, 2021 at 7:00 AM EDT PDF Version -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- -Best Corrected Visual Acuity (BCVA…

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020

February 11, 2021 at 7:00 AM ESTPDF Version – Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 – – Net proceeds of approximately $69.2 million from a recent public offering provide cash runway into calendar year 2023 – – Company to host conferen…
Show more

Applied Genetic Technologies Frequently Asked Questions

  • When was Applied Genetic Technologies founded?

    Applied Genetic Technologies was founded in 1991.

  • Who are Applied Genetic Technologies key executives?

    Applied Genetic Technologies's key executives are Stephen W. Potter, david R. Knop and Sue Washer.

  • How many employees does Applied Genetic Technologies have?

    Applied Genetic Technologies has 85 employees.

  • What is Applied Genetic Technologies revenue?

    Latest Applied Genetic Technologies annual revenue is $2.5 m.

  • What is Applied Genetic Technologies revenue per employee?

    Latest Applied Genetic Technologies revenue per employee is $28.9 k.

  • Who are Applied Genetic Technologies competitors?

    Competitors of Applied Genetic Technologies include MultiVir, Harbour BioMed and Celularity.

  • Where is Applied Genetic Technologies headquarters?

    Applied Genetic Technologies headquarters is located at 14193 NW 119th Terrace Ste 10, Alachua.

  • Where are Applied Genetic Technologies offices?

    Applied Genetic Technologies has offices in Alachua and Cambridge.

  • How many offices does Applied Genetic Technologies have?

    Applied Genetic Technologies has 2 offices.